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Dm) for same number of monitor units and identical beam 
setup. Several parameters were analyzed for the PTV: D95%, 
D5%, Dmax, V100%, V50%, Homogeneity Index HI=D5%/D95% and 
Conformity Indices 100% and 50% CIX%=VX%/VPTV. Following the 
dose constraints from the AAPM TG101, values were reported 
for various critical organs: spinal cord, oesophagus, heart, 
great vessels, trachea and large bronchus, ribs and healthy 
lungs. Two-tailed paired t-tests were used to analyze the 
differences between AXB (Dw) and AAA (Dw) and between AXB 
(Dm) and AXB (Dw). F-tests were used to compare the 
variances of the populations. A significance level α=0.05 was 
chosen. 
Results: For PTV, statistically significant differences were 
observed between AAA (Dw) and AXB (Dw) for V100%, V50% and 
CI100%. While V100% was higher for AXB (Dw), V50% was lower. D95%, 
V100%, CI100% and HI values were lower for AXB (Dm) compared 
to AXB (Dw). Variance analyses showed significant differences 
in HI in all cases. For OAR, AXB (Dw) doses were lower than 
AAA (Dw), except for ribs, were photoelectric effect is 
correctly predicted by AXB. On the other hand AXB (Dm) doses 
were lower than AXB (Dw). Not all these differences were 
significant. F-tests showed no differences in populations 
variances. Observed differences arise from AXB superior 
radiation transport modelling and the effects of mapping CT 
images to materials in AXB. All these differences are not 
clinically relevant as they are comparable to dose calculation 
uncertainties, but plan normalization based on isodose 
coverage may be altered. 
Conclusions: Several statistically significant differences can 
be observed in dose prescription and dose-volume reporting 
to the PTV and OAR of lung SBRT treatments between AXB 
(Dw), AAA (Dw) and AXB (Dm). These differences are not 
clinically relevant although plan normalization may be 
altered.  
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Purpose/Objective: The aim of this study was to evaluate 
and compare the efficiency between two different VMAT 
techniques for stereotactic body radiotherapy (SBRT) in 
peripheral lung tumors. 
Materials and Methods: Five patients with a single peripheral 
lung tumor smaller than 50 cc (range 12.4, 48.6 cc) were 
included in this study. Two different VMAT plans were 
created for each patient. The first plan was performed using 
one-arc rotating 360º (1ARC). The second plan was performed 
using one-arc rotating 180º, from 180º to 0º, at the ipsilateral 
side of the affected lung (1SEMIARC). Both plans were 
calculated by the Monaco treatment planning system (version 
3.30.01), using 6 MV photons generated from Elekta Synergy 
Beam Modulator linac. Three risk-adapted fractionation 
schemes were used (3 fractions of 18 Gy, 3 fractions of 16 
Gy, and 5 fractions of 10 Gy). The objectives for PTV and 
organs at risk (OAR) matched to those used in ROSEL 
protocol. Both plans were normalized to deliver 100% of 
prescribed dose to 98% of PTV. Dosimetry comparison was 
made in terms of the percentage of healthy lung receiving a 
minimum biological equivalent dose of 20 Gy (HLV20) and the 
percentage of contralateral lung receiving a minimum 
biological equivalent dose of 5 Gy (CLV5). Paddick conformity 
index (PCI), RTOG homogeneity index (HI) and the maximum 
absorbed dose to spinal cord, esophagus and heart were also 
compared. Monitor units per gray (MU/Gy) and treatment 
delivery time (TDT), excluding any time needed for 
additional imaging and set-up, were also measured for 
treatment delivery efficiency comparison. A descriptive 
analysis (mean ± SD) of every variable was obtained for both 
plans in each patient. Dosimetry comparison between both 
plans was performed using a two-sided Student's t test. 
Differences were considered statistically significant if p < 
0.05. 
Results: DVH analysis revealed that all plans created for each 
patient fulfilled the specified dose constraints. TDT was 
reduced by 27.3 % (p < 0.001) for 1SEMIARC compared with 
1ARC, for the 18 Gy fraction scheme. 1SEMIARC plans 
achieved lower CLV5 compared with 1ARC plans (difference of 
49.9%, p < 0.02) 1SEMIARC plans showed similar PCI, HI, HLV20 
and maximum doses to the OARs compared with 1ARC plans 
(p > 0.05). See Table I. 
 
 
 
Table I: Summary of study parameters between the two 
treatment techniques (mean ± SD) 
 
Conclusions: The result of this study comparing two different 
VMAT techniques for the treatment of peripheral lung 
tumors, confirms the ability of one-arc VMAT field, rotating 
180º at the ipsilateral side of the lung, to deliver highly 
conformed dose distributions. In addition to the dosimetric 
gains in the contralateral lung, one-arc VMAT field rotating 
180º technique achieve a shorter treatment time, 
accomplishing a reduction of the risk of intrafraction baseline 
shifts in tumor position, compared with one-arc VMAT field 
rotating 360º technique. 
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Purpose/Objective: To assess both plan quality criteria and 
optimization efficiency of automatically generated VMAT 
treatment plans for prostate cancer including seminal 
vesicles and lymph nodes. 
Materials and Methods: Manually (MP) and automatically (AP) 
generated VMAT treatment plans (Pinnacle© TPS V9.10, 
X4170 Smart-Enterprise) were compared for 10 prostate 
cancer cases. Each treatment plan (TP) contained a primary 
target volume (PTV) including prostate, seminal vesicles and 
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lymph nodes and a boost volume including the prostate and 
seminal vesicles; TPs were generated in simultaneous boost 
technique. For AP, a progressive engine is used where the 
user defines prioritized optimization goals for PTV-coverage 
and dose thresholds and priorities for each organ at risk 
(OAR). The AP engine automatically creates objectives and 
required optimization aid structures (OAS), and multiple 
optimization loops iteratively reformulate and adjust the 
optimization objectives to meet the goals and further lower 
dose to OAR with minimal compromise to the target 
coverage. For manual planning, additional OAS have to be 
generated by the planner, objectives and priorities have to 
be adjusted manually for each optimization loop. For plan 
comparison, various dose and dose volume metrics (Dmed, 
D98%, D2% V95% for target volumes, D2%, Dmed and Vx% for OARs) as 
well as homogeneity index (HI = (D2%-D98%)/ D50%) and 
conformity index (CIPaddick = TV²PI/(PI*TV)) were evaluated. 
Efficiency of the plan optimization procedure was estimated 
by means of total time required to create a TP. 
Results: PTV coverage V95% was 93.5±3.5% and 97.9±1.3% and 
boost coverage was 95.5±2.0% and 98.3±1.7% for MP and AP, 
respectively. Homogeneity index for the PTV was 0.14±0.02 
and 0.12±0.02 and for the boost it was 0.11±0.02 and 
0.07±0.02 for MP and AP, respectively. CI was 13% and 16% 
higher in manual plans compared to automatic plans for PTV 
and boost, respectively. Dmed and D2% for bladder and femoral 
heads showed no particular differences between manual and 
automatic plans. However, considerable deviations in Dmed 
were found for the rectum (27.8±4.7Gy vs 33.3±5.8Gy for MP 
and AP, respectively) and intestine (25.2±7.5Gy and 
22.8±8.2Gy for MP and AP, respectively). Further, VTissue30% 
representing tissue outside the target volumes received 36% 
more dose in AP compared to MP. The time to create a 
treatment plan was <1 hour for MP and >2 hours for AP. 
Conclusions: Automatically generated TPs improve target 
coverage and homogeneity at the cost of slightly decreased 
conformity when compared to manual TPs. OAR sparing is 
mostly comparable, higher dose contribution to normal tissue 
outside the PTV was found for AP. Since higher low dose 
volume was detected in normal tissue for AP plans, each TP 
needs to be evaluated by an experienced planner and 
adapted when necessary. Prioritized optimization goals in AP 
need to be carefully established and the overall time 
required to create a plan remains to be optimized. 
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Purpose/Objective: Knowledge based planning software 
RapidPlanTM was used to develop a pre-configured planning 
model for 5-field IMRT prostate plans. Prostates were 
planned to 78 Gy, seminal vesicles to 60 Gy and an 
intermediate shell, grown from prostate, to 71 Gy. This study 
describes the steps undertaken to create, test and develop a 
model to generate clinically acceptable prostate plans. 
Materials and Methods: Preparing and optimizing a model for 
clinical use consisted of 2 stages: training the dose prediction 
algorithm using a library of approved clinical plans; and 
defining how dose predictions were used to generate patient-
specific objectives in the IMRT optimizer. Structures and dose 
distributions from previously-treated prostate patients were 
used to train the model. Sufficient plans, 41 initially, were 
added as directed by initial statistical analyses to ensure the 
model was adequately trained for all structures. Analysis of 
potential outliers was then carried out to exclude patients 
that would adversely influence the model outcome. 3 types 
of model were created: i) all plans included; ii) the most 
extreme outliers were excluded (e.g. patients with prosthetic 
hips); iii) all patients identified as outliers by RapidPlan were 
excluded. The resulting models were then used to generate 
plans for 5 patients who had not been included in the 
modelling process. Plan optimization objectives consisted of 
a line objective and maximum dose point objective for each 
OAR, and minimum and maximum point objectives for all 
PTVs. Comparisons of generated plans with corresponding 
clinical plans were carried out to indicate required changes 
to the models. Model parameters were then iteratively 
adjusted until plan quality converged with that of the clinical 
plans for the test patients.  
Results: A number of changes to the initial model were 
required. These included setting the normal tissue objectives 
from the default to those used clinically in local IMRT 
protocols while maintaining the default smoothing 
parameters set. For the final version of the model, plans 
created using the RapidPlan model were similar to the 
equivalent plans devised by experienced planners and used 
clinically (Figure 1, Table 1). In some cases PTV coverage was 
slightly reduced in the superior and inferior edges for 
RapidPlan plans compared with clinical plans. OAR doses 
were similar for both RapidPlan and clinical plans. No 
significant difference was seen between the performance of 
models i), ii) and iii).  
 
Figure 1. Comparison of RapidPlan (left) and Clinical (right) 
plan dose distributions. 
Table 1. Table comparing PTV parameters of plans generated 
using the final two RapidPlan models, v5 & v4d, which are 
versions of model ii) and the corresponding clinical plan. 
 
 
 
Conclusions: This study has highlighted the potential of the 
